Cost Effectiveness of Fulvestrant 500 Mg in Endocrine Therapy-Naïve Women with Hormone Receptor-Positive Advanced Breast Cancer in The UK

OBJECTIVES: Fulvestrant is approved for the treatment of hormone receptor (HR)-positive advanced breast cancer (ABC) after progression on anti-estrogen therapy, and in combination with palbociclib, for HR-positive, human epidermal growth factor receptor 2 (HER2)-negative ABC after disease progressio...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Value in health 2017-10, Vol.20 (9), p.A435
Hauptverfasser:	Livings, C, Jones, N, Bertranou, E, Large, S, Phelps, H, Ekman, M, Telford, C
Format:	Artikel
Sprache:	eng
Schlagworte:	Anastrozole Antiestrogens Breast cancer Cancer Clinical significance Combination therapy Cost analysis Costs Critical incidents Disease Disease management Effectiveness End of life decisions Endocrine therapy Epidermal growth factor ErbB-2 protein Estrogens Fulvestrant Growth hormones Health care expenditures Health services Hormone replacement therapy Hormones Literature reviews Patients Quality adjusted life years Quality of life Social services Survival Tamoxifen Therapy Time Treatment methods Women
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!